Business Context and Reporting Period
Company: ChromaDex Corporation (Note: Input metadata referenced "Niagen Bioscience, Inc.", but the filing text identifies the registrant as ChromaDex Corporation).
Filing Type: Form 8-K (Current Report)
Date of Report: September 29, 2014
Event: Entry into a Material Definitive Agreement (Loan and Security Agreement) with Hercules Technology II, L.P.
Key Financial Metrics and Debt Structure
This filing details a new debt facility rather than reporting period-end financial results (revenue, profit, or cash flow are not provided in this document).
- Total Term Loan Capacity: Up to $5,000,000.
- Initial Funding: $2,500,000 funded at closing.
- Remaining Availability: $2,500,000 available for drawdown at the Company's option until July 31, 2015.
- Interest Rate: Variable; the greater of (i) 9.35% + Prime Rate - 3.25% or (ii) 9.35%.
- Repayment Terms: 30-month installment period following a 12-month interest-only period.
- Upfront Costs: $50,000 facility charge paid at closing.
- End of Term Charge: 3.75% of all amounts drawn, payable at maturity or prepayment.
- Prepayment Penalties: 3% (first 12 months), 2% (next 12 months), 1% (thereafter).
- Collateral: First priority liens on substantially all assets, excluding intellectual property and 35% of foreign subsidiary capital stock.
Material Changes and Equity Components
The Company entered into a new financing arrangement that introduces significant debt obligations and potential equity dilution.
- Conversion Feature: Up to $1,000,000 of principal may be converted into common stock at a price of $1.293 per share. Conversion is split 50% at the Lender's option and 50% at the Company's option.
- Warrant Issuance: The Company issued a warrant to purchase 419,020 shares of common stock at an exercise price of $1.062 per share. The warrant is exercisable immediately and expires in five years.
- Default Interest: An additional 4% interest rate applies upon an event of default.
Guidance, Risks, and Covenants
Management Commentary and Risks: The filing highlights risks regarding insufficient cash flows to meet debt obligations, vulnerability to economic conditions, and limitations on obtaining additional financing. The Company notes that failure to meet obligations could force asset sales, capital expenditure reductions, or debt restructuring.
Covenants: The agreement includes restrictive covenants limiting the Company's ability to incur additional debt, grant liens, make investments, sell assets outside the ordinary course, or make fundamental business changes. There are no financial covenants specified.
Dividends: The agreement contains covenants that may limit the ability to pay dividends.
Investor Verification Checklist
- Verify the current Prime Rate to calculate the exact effective interest rate on the loan.
- Confirm the Company's current cash position and operating cash flow to assess ability to service the $2.5M initial debt during the interest-only period.
- Review the impact of the warrant (419,020 shares) and potential conversion shares on existing shareholder dilution.
- Check for any subsequent filings regarding the drawdown of the remaining $2.5M tranche.
- Monitor compliance with restrictive covenants regarding additional indebtedness and asset sales.